Drug Profile
Research programme: ATM kinase inhibitors - Pfizer/ St. Jude Childrens Research Hospital
Alternative Names: CP 466722Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Pfizer; St. Jude Childrens Research Hospital
- Class
- Mechanism of Action Ataxia telangiectasia mutated protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Sep 2008 Preclinical trials in cancer in USA